| Popis: |
Therapy of tuberculosis has been hailed as one of the great achievements of the mid-20th century. The remarkable efficacy of shortcourse chemotherapy (SCC) as developed by the British Medical Research Council and others is now well established. However, problems of long duration, complexity, toxicity, failure of intermittency to succeed in important subpopulations, and pharmacokinetic variability persist. Some of the evidence for the success of SCC is presented, as are some of the reasons why alternatives are being sought. |
